Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Lung Neoplasms 15Neoplasms 2NSCLC 2Breast Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Sexual Dysfunction, Physiological 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-Small Cell Lung Cancer With EGFR Mutation 1Non Small Cell Lung Cancer Metastatic 1NSCLC Patients With Brain Metastasis 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma 1Meningeal Carcinomatosis 1Lung Cancer Metastatic 1Locally Advanced or Metastatic Non-squamous NSCLC 1Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) 1Lethal Congenital Contracture Syndrome 2 1Head and Neck Neoplasms 1Eunuchism 1Erectile Dysfunction 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Advanced Solid Tumors 1Adenocarcinoma of Lung 1

Interventions

Injections 16pembrolizumab 6Bevacizumab 6Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4fludarabine 3Pemetrexed 3Oxaliplatin 3Capecitabine 3toripalimab 2sotorasib 2Immune Checkpoint Inhibitors 2Fulvestrant 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2zimberelimab 1trifluridine tipiracil drug combination 1trametinib 1tislelizumab 1sacituzumab govitecan 1palbociclib 1osimertinib 1olaparib 1lazertinib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumors × osimertinib × Clear all
NCT06895928 2025-04-22

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2 Recruiting
400 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡